Rare diseases
Investigational molecules
Locations
1 Design Center Place Suite 17-500, 02210-2349, United States
Entrada Therapeutics Inc. focuses its clinical research on Duchenne muscular dystrophy, with studies targeting patients whose disease is amenable to exon 44 skipping and exon 45 skipping.
The sponsor’s active trial portfolio includes recruiting studies across multiple countries and research sites, reflecting a concentrated interest in treatment areas relevant to DMD and its molecular subtypes.
Entrada Therapeutics Inc. runs clinical trials in conditions such as Duchenne muscular dystrophy, Duchenne muscular dystrophy gene carrier, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy
BelgiumStudy of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45
BelgiumStudy of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
